Browse drugs

…epant: 5 changed from erenumab, 2 from galcanezumab, and 1 from galcanezumab. There were 11 line changes to eptinezumab: 5 from erenumab, 4 …

…ement.Results A total of 1,992 drug interactions were analysed: apixaban 531 (26.7%), dabigatran 492 (24.7%), edoxaban 411 (20.6%), riva…

….7), piperacillin 59.15 (22.1–59.4), cefepime 64.8 (29.9–99.7), ceftazidime 59.4 (32.6–73.2); single values: ceftolozane 53.4, aztreonam 36…

…mean current age of 45.3 years. Biologic therapies consisted of Belimumab in 47 patients (56.0%), Anifrolumab in 26 (31.0%), and Rituxima…

…xel arm. Grade 5 haemoptysis occurred in 3 (1.6%) patients with sitravatinib plus tislelizumab. The study was terminated due to an unfavoura…

… a dose of 0.5-1x10e7 cells/animal once every week for 5 weeks. Dinutuximab was administered via IP injection at 15 ug/animal twice a week.…

…05755Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and …

…k sac of zebrafish embryos, followed by systemic treatment with Docetaxel. Tumor burden was quantified using fluorescence microscopy, and…

… S, Wong A, Yong WP, Soo RA, Chee CE, Tan DS. 458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Ca…

…and 89.5% OS) compared with 450 µg/kg (38.7% PFS and 69.4% OS). Mitazalimab in combination with mFOLFIRINOX demonstrated a manageable safet…

…okine and cytolysis molecule production (figure 2B).Conclusions REPO is a fluorescent small molecule that differentially stains T ce…

…ion for IMGS-203 as a treatment for GBM. The advantage of using IMGS-203 to treat GBM is that it does not need to be delivered to every …